TENX Projected Dividend Yield
Tenax Therapeutics Inc ( NASDAQ : TENX )Tenax Therapeutics is focused on identifying, developing and commercializing late-stage pharmaceutical therapeutic products for cardiovascular and pulmonary diseases. Co. owns a license granting Life Newco, Inc., its wholly owned subsidiary, a sublicensable right to develop and commercialize pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion / 5ml vial in the U.S. and Canada. Co.'s programs include: Levosimendan, which is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib (marketed in the U.S. as Gleevec®), which is a tyrosine kinase inhibitor. 20 YEAR PERFORMANCE RESULTS |
TENX Dividend History Detail TENX Dividend News TENX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |